| Latest Aventis News Headlines |
| Date | Time | Source | |
| 10/15/2004 | 4:03PM | PRNUS | Rhone-Poulenc Overseas Limited Announces Redemption of All Outstanding Cumulative Guaranteed Preference Shares, Series A
Rhone-Poulenc Overseas Limited Announces Redemption of All
Outstanding Cumulative Guaranteed Preference Shares, Series A
NEW YORK, Oct. 15 /PRNewswire-FirstCall/ -- Rhone-Poulenc Overseas Limited
(NYSE:RPONYSE:PrA) (the "Company") announced today that, pursuant to a decision
of its Board of Directors dated October 7... More...>> |
| 10/04/2004 | 2:44PM | PRNUS | Aventis Ships 30 Million Doses of Influenza Vaccine to Health-Care Providers
Aventis Ships 30 Million Doses of Influenza Vaccine to
Health-Care Providers
Pre-Booked Customers Received Partial or Full Influenza Vaccine Order in
September; Balance to be Shipped in October/November
SWIFTWATER, Pa., Oct. 4 /PRNewswire-FirstCall/ -- Aventis (NYSE:AVE), part of
the sanofi-aventis Group, announced... More...>> |
| 09/22/2004 | 4:23PM | PRNUS | Advisory Panel Recommends FDA Licensure of Aventis' Menactra(TM) Vaccine for Protection Against Meningococcal Disease
Advisory Panel Recommends FDA Licensure of Aventis' Menactra(TM)
Vaccine for Protection Against Meningococcal Disease
- First Candidate Quadrivalent Conjugate Meningococcal Vaccine -
SWIFTWATER, Pa., Sept. 22 /PRNewswire-FirstCall/ -- Aventis (NYSE:AVE), part
of the sanofi-aventis Group, announced today that the Vaccines... More...>> |
| 09/14/2004 | 8:30AM | PRNUS | Coley Pharmaceutical Group Receives Payment From Aventis for Clinical Milestone in Collaboration on Allergic Respiratory Disease
Coley Pharmaceutical Group Receives Payment From Aventis for
Clinical Milestone in Collaboration on Allergic Respiratory Diseases
WELLESLEY, Mass., Sept. 14 /PRNewswire/ -- Coley Pharmaceutical Group, Inc.
today announced that the company has received a $5 million milestone payment
from Aventis (NYSE:AVE). The payment... More...>> |
| 08/19/2004 | 8:00AM | PRNUS | FDA Approves Taxotere(R) for the Treatment of Women with Early Stage Breast Cancer
FDA Approves Taxotere(R) for the Treatment of Women with Early
Stage Breast Cancer
Earlier use of Taxotere(R) shown to significantly improve disease-free survival
by reducing the risk of relapse in women with node-positive breast cancer
BRIDGEWATER, N.J., Aug. 19 /PRNewswire/ -- Aventis (NYSE:AVE) announced today
that... More...>> |
| 08/11/2004 | 10:39AM | PRNUS | Aventis Submits Application for FDA Licensure of ADACEL(TM) Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adole
Aventis Submits Application for FDA Licensure of ADACEL(TM)
Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and
Adults
- Vaccine Leader Looks to Introduce Pertussis Booster in United States -
SWIFTWATER, Pa., Aug. 11 /PRNewswire-FirstCall/ -- Aventis (NYSE:AVE) today
announced the submission... More...>> |
| 08/05/2004 | 7:02PM | PRNUS | Ventiv Health Announces Sales and Marketing Agreement with Aventis
Ventiv Health Announces Sales and Marketing Agreement with
Aventis
Contract Calls for Over 450 Sales Representatives Focused on Primary Care and
Specialist Markets
SOMERSET, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Ventiv Health, Inc.
(NASDAQ:VTIV) announced today that it has signed a sales and marketing
agreement with... More...>> |
| 08/03/2004 | 1:58PM | PRNUS | FDA Approves Sculptra(TM) (Injectable Poly-L-Lactic Acid)
FDA Approves Sculptra(TM) (Injectable Poly-L-Lactic Acid)
BERWYN, Penn., Aug. 3 /PRNewswire/ -- Dermik Laboratories, the US dermatology
arm of Aventis (NYSE:AVE), announced today that the US Food and Drug
Administration (FDA) has approved SCULPTRA(TM) (injectable poly-L-lactic acid)
as the only product for the restoration... More...>> |
| 07/28/2004 | 2:31PM | PRNUS | Aventis Reports Second-Quarter and First-Half Results for 2004
Aventis Reports Second-Quarter and First-Half Results for 2004
All figures refer to 2004 Group vs. 2003 Core unless otherwise stated
STRASBOURG, France, July 28 /PRNewswire-FirstCall/ --
Aventis Q2 results
* Total revenues, including co-promotion income, rise 5.2% on activity
growth to EUR 4.308 billion... More...>> |
| 06/07/2004 | 12:00PM | PRNUS | Two Landmark Studies Show That Taxotere(R) Significantly Improves Survival in Men With Prostate Cancer
Two Landmark Studies Show That Taxotere(R) Significantly Improves
Survival in Men With Prostate Cancer
Taxotere(R)-based regimen is the first and only treatment with proven
significant survival benefit for men with androgen-independent
(hormone-refractory) metastatic prostate cancer
BRIDGEWATER, N.J., June 7 /PRNewswire-FirstCall/... More...>> |
| 06/05/2004 | 9:00AM | PRNUS | Investigators Report Taxotere(R) Offers Significant Survival Benefits for Head and Neck Cancer Patients
Investigators Report Taxotere(R) Offers Significant Survival
Benefits for Head and Neck Cancer Patients
BRIDGEWATER, N.J., June 5 /PRNewswire-FirstCall/ -- Aventis (NYSE:AVE)
announced today the results of a phase III trial using Taxotere(R) (docetaxel)
Injection Concentrate when added to a standard therapy for nonresectable
locally... More...>> |
| 05/28/2004 | 12:00PM | PRNUS | Genta and Aventis Announce Termination of Genasense(TM) Expanded Access Program in Melanoma
Genta and Aventis Announce Termination of Genasense(TM) Expanded
Access Program in Melanoma
BERKELEY HEIGHTS and BRIDGEWATER, N.J., May 28 /PRNewswire-FirstCall/ -- Genta
Incorporated (NASDAQ:GNTA) and Aventis (NYSE:AVE) today announced the
termination of the Expanded Access Program (EAP) for Genasense(TM) (oblimersen
sodium... More...>> |
| 05/26/2004 | 8:00AM | PRNUS | Two Landmark Studies of Taxotere(R) in Prostate Cancer Highlighted in American Society of Clinical Oncology Plenary Session
Two Landmark Studies of Taxotere(R) in Prostate Cancer
Highlighted in American Society of Clinical Oncology Plenary Session
BRIDGEWATER, N.J., May 26 /PRNewswire-FirstCall/ -- Aventis announced today
that two landmark Phase III studies of Taxotere(R) (docetaxel) Injection
Concentrate in men with androgen-independent... More...>> |
| 05/19/2004 | 2:39PM | PRNUS | Aventis Receives FDA Approval for Taxotere(R) in Prostate Cancer
Aventis Receives FDA Approval for Taxotere(R) in Prostate Cancer
BRIDGEWATER, N.J., May 19 /PRNewswire-FirstCall/ -- Aventis announced today
that the U.S. Food and Drug Administration (FDA) has approved Taxotere(R)
(docetaxel) Injection Concentrate for use in combination with prednisone as a
treatment for men with... More...>> |
| 05/03/2004 | 2:52PM | PRNUS | FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced Melanoma
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced
Melanoma
BERKELEY HEIGHTS, N.J. and BRIDGEWATER, N.J., May 3 /PRNewswire-FirstCall/ --
Genta Incorporated and Aventis presented results of their Phase 3 trial of
Genasense(TM) (oblimersen sodium) Injection in combination with dacarbazine
(DTIC) versus... More...>> |
| 04/20/2004 | 8:30AM | PRNUS | Genta and Aventis Announce Genasense(TM) Expanded Access Program for Patients with Advanced Melanoma
Genta and Aventis Announce Genasense(TM) Expanded Access Program
for Patients with Advanced Melanoma
BERKELEY HEIGHTS and BRIDGEWATER, N.J., April 20 /PRNewswire-FirstCall/ --
Genta Incorporated and Aventis today announced the availability of
Genasense(TM) (oblimersen sodium) Injection for use in combination with
dacarbazine... More...>> |
| 04/15/2004 | 8:00AM | PRNUS | Aventis Announces FDA Approval of Nasacort(R) HFA (triamcinolone acetonide) Nasal Aerosol
Aventis Announces FDA Approval of Nasacort(R) HFA (triamcinolone
acetonide) Nasal Aerosol
First HFA Nasal Aerosol Available to Treat Nasal Allergy Symptoms
BRIDGEWATER, N.J., April 15 /PRNewswire-FirstCall/ -- Aventis today announced
that the U.S. Food and Drug Administration (FDA) has approved Nasacort HFA
(triamcinolone... More...>> |
| 04/01/2004 | 4:56PM | PRNUS | Aventis Announces FDA Approval of KETEK(TM) (Telithromycin) Tablets
Aventis Announces FDA Approval of KETEK(TM) (Telithromycin)
Tablets
First-in-class antibiotic to treat mild to moderate community-acquired
respiratory tract infections
BRIDGEWATER, N.J., April 1 /PRNewswire-FirstCall/ -- Aventis today announced
that the U.S. Food and Drug Administration (FDA) has approved KETEK(TM)
(telithromycin... More...>> |
| 03/26/2004 | 11:47AM | PRNUS | SCULPTRA(TM) From Dermik Laboratories Receives Recommendation for Approval With Conditions From FDA Advisory Panel
SCULPTRA(TM) From Dermik Laboratories Receives Recommendation for Approval With
Conditions From FDA Advisory Panel
BERWYN, Pa., March 26 /PRNewswire/ -- Dermik Laboratories, the U.S. dermatology
arm of Aventis , announced today that a U.S. Food and Drug Administration (FDA)
advisory committee has unanimously recommended... More...>> |
| 03/16/2004 | 1:17PM | PRNUS | Atrix Signs Feasibility Agreement for Development of Two Aventis Compounds
Atrix Signs Feasibility Agreement for Development of Two Aventis Compounds
FORT COLLINS, Colo., March 16 /PRNewswire-FirstCall/ -- Atrix Laboratories,
Inc. announced today that the company has signed a limited feasibility
agreement with Aventis SA to begin preliminary research on two proprietary
Aventis compounds formulated... More...>> |